Pravastatin decreases blood pressure in hypertensive and hypercholesterolemic patients receiving antihypertensive treatment

Circulation Journal

Volumn 70, Issue 9, 2006, Pages 1116-1121

  Kawano, Hiroaki ^a   Yano, Katsusuke ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

Antihypertensive drugs; Blood pressure; Hyperlipidemia; Hypertension; Statins

Indexed keywords

ANTIHYPERTENSIVE AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; BLOOD PRESSURE; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; PRAVASTATIN; RETROSPECTIVE STUDIES;

EID: 33748654254     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.70.1116     Document Type: Article

References (53)

1. Kannel WB. Blood pressure as a cardiovascular risk factor: Prevention and treatment. JAMA 1996; 275: 1571-1576.
2. Julius S. Clinical implications of pathophysiologic changes in the midlife hypertensive patient. Am Heart J 1991; 122: 886-891.
3. Njolstad I, Arnesen E, Lund-Larsen PG. Smoking, serum lipids, blood pressure, and sex differences in myocardial infarction: A 12-year follow-up of the Finnmark Study. Circulation 1996; 93: 450-456.
4. Goode GK, Miller JP, Heagerty AM. Hyperlipidaemia, hypertension, and coronary heart disease. Lancet 1995; 345: 362-364.
5. Lewis TV, Cooper BA, Dart AM, Chin-Dusting JP. Responses to endothelium-dependent agonists in subcutaneous arteries excised from hypercholesterolaemic men. Br J Pharmacol 1998; 124: 222-228.
6. Wever R, Stroes E, Rabelink TJ. Nitric oxide and hypercholesterolemia: A matter of oxidation and reduction? Atherosclerosis 1998; 137(Suppl): S51-S60.
7. Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995; 346: 467-471.
8. O'Donnell MP, Kasiske BL, Katz SA, Schmitz PG, Keane WF. Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. Hypertension 1992; 20: 651-658.
9. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450-1457.
10. Wilson TW, Alonso-Galicia M, Roman RJ. Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension 1998; 31: 225-231.
11. Jiang J, Sun CW, Alonso-Galicia M, Roman RJ. Lovastatin reduces renal vascular reactivity in spontaneously hypertensive rats. Am J Hypertens 1998; 11: 1222-1231.
12. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999; 34: 1281-1286.
13. Ferrier KE, Muhlmann MH, Baguet JP, Cameron JD, Jennings GL, Dart AM, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39: 1020-1025.
14. Sposito AC, Mansur AP, Coelho OR, Nicolau JC, Ramires JA. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999; 83: 1497-1499.
15. Borghi C, Prandin MG, Costa FV, Bacchelli S, Degli Esposti D, Ambrosioni E. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000; 35: 549-555.
16. Borghi C, Dormi A, Veronesi M, Sangiorgi Z, Gaddi A. Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am Heart J 2004; 148: 285-292.
17. Ikeda T, Sakurai J, Nakayama D, Takahashi Y, Matsuo K, Shibuya Y, et al. Pravastatin has an additional depressor effect in patients undergoing long-term treatment with antihypertensive drugs. Am J Hypertens 2004; 17: 502-506.
18. Muramatsu J, Kobayashi A, Hasegawa N, Yokouchi S. Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin. Atherosclerosis 1997; 130: 179-182.
19. Antonicelli R, Onorato G, Pagelli P, Pierazzoli L, Paciaroni E. Simvastatin in the treatment of hypercholesterolemia in elderly patients. Clin Ther 1990; 12: 165-171.
20. Kool M, Lustermans F, Kragten H, Struijker Boudier H, Hoeks A, Reneman R, et al. Does lowering of cholesterol levels influence functional properties of large arteries? Eur J Clin Pharmacol 1995; 48: 217-223.
21. Sartor G, Katzman P, Eizyk E, Kalen J, Nilsson A, Ugander L, et al. Simvastatin treatment of hypercholesterolemia in patients with insulin dependent diabetes mellitus. Int J Clin Pharmacol Ther 1995; 33: 3-6.
22. Sung BH, Izzo JL Jr, Wilson MF. Effects of cholesterol reduction on BP response to mental stress in patients with high cholesterol. Am J Hypertens 1997; 10: 592-599.
23. van Etten RW, de Koning EJ, Honing ML, Stroes ES, Gaillard CA, Rabelink TJ. Intensive lipid lowering by statin therapy does not improve vasoreactivity in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 2002; 22: 799-804.
24. D'Agostino RB, Kannel WB, Stepanians MN, D'Agostino LC. Efficacy and tolerability of lovastatin in hypercholesterolemia in patients with systemic hypertension. Am J Cardiol 1993; 71: 82-87.
25. O'Callaghan CJ, Krum H, Conway EL, Lam W, Skiba MA, Howes LG, et al. Short term effects of pravastatin on blood pressure in hypercholesterolaemic hypertensive patients. Blood Press 1994; 3: 404-406.
26. Fogari R, Zoppi A, Lusardi P, Preti P, Poletti L, Salvetti A. Effects of pravastatin given every other day in dyslipidemic hypertensive patients treated with different antihypertensive drugs. High Blood Press 1996; 5: 219-225.
27. Dormi A, Gaddi A, Borghi C. Lipid-lowering drugs and blood pressure control in patients at high CV risk: Evidences from a population survey in the Brisighella Heart Study. J Hypertens 1999; 17: 60.
28. Tonolo G, Melis MG, Formato M, Angius MF, Carboni A, Brizzi P, et al. Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000; 30: 980-987.
29. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89: 2519-2524.
30. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-1131.
31. Vogel RA, Corretti MC, Plotnick GD. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middLe-aged men. Am J Cardiol 1996; 77: 37-40.
32. John S, Schlaich M, Langenfeld M, Weihprecht H, Schmitz G, Weidinger G, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: A randomized, placebo-controlled, double-blind study. Circulation 1998; 98: 211-216.
33. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-1135.
34. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999; 33: 234-241.
35. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101: 2711-2719.
36. Leclercq B, Jaimes EA, Raij L. Nitric oxide synthase and hypertension. Curr Opin Nephrol Hypertens 2002; 11: 185-189.
37. 2+ release and vascular reactivity. J Cardiovasc Pharmacol 1999; 34: 95-101.
38. Ide H, Fujiya S, Aanuma Y, Agishi Y. Effects of simvastatin, an HMG-CoA reductase inhibitor, on plasma lipids and steroid hormones. Clin Ther 1990; 12: 410-420.
39. Koh KK, Son JW, Ahn JY, Kim DS, Jin DK, Kim HS, et al. Simvastatin combined with ramipril treatment in hypercholesterolemic patients. Hypertension 2004; 44: 180-185.
40. Biegelsen ES, Loscalzo J. Endothelial function and atherosclerosis. Coron Artery Dis 1999; 10: 241-256.
41. Nickenig G, Sachinidis A, Michaelsen F, Bohm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997; 95: 473-478.
42. Nickenig G, Jung O, Strehlow K, Zolk O, Linz W, Scholkens BA, et al. Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression. Am J Physiol 1997; 272: H2701-H2707.
43. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131-2134.
44. Terada Y, Saito T, Fujiwara Y, Hasegawa H, Miura H, Watanabe H, et al. Pitavastatin inhibits upregulation of intermediate conductance calcium-activated potassium channels and coronary arteriolar remodeling induced by long-term blockade of nitric oxide synthesis. Pharmacology 2003; 68: 169-176.
45. White HD, Simes RJ, Anderson NE, Hankey GJ, Watson JD, Hunt D, et al. Pravastatin therapy and the risk of stroke. N Engl J Med 2000; 343: 317-326.
46. Waters DD, Schwartz GG, Olsson AG, Zeiher A, Oliver MF, Ganz P, et al; MIRACL Study Investigators. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: A Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 2002; 106: 1690-1695.
47. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
48. Sacks FM, Pfeffer MA, Moye LA, Rouleau JR, Rutherford JD, Code TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009.
49. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlene PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevension Study Group. N Engl J Med 1995; 333: 1301-1307.
50. Mabuchi H, Kita T, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholeterolemia and coronary heart disease: Second prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J 2002; 66: 1096-1100.
51. Matsuzaki M, Kita T, Mabuchi H, Matsuzawa Y, Nakaya N, Oikawa S, et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simbastatin therapy in Japanese patients with hypercholesterolemia. Circ J 2002; 66: 1087-1095.
52. Iwashita M, Matsushita Y, Sasaki J, Arakawa K, Kono S; Kyushu Lipid Intervention Study (KLIS) Group. Relation of serum total cholesterol and other factors to risk of cerebral infarction in Japanese men with hypercholesterolemia. Circ J 2005; 69: 1-6.
53. Nishikawa H, Miura S, Zhang B, Shimomura H, Arai H, Tsuchiya Y, et al. Statins induce the regression of left ventricular mass in patients with angina. Circ J 2004; 68: 121-125.